Residual schizophrenia is a former diagnostic subtype of schizophrenia used to describe a phase where the intense symptoms, such as hallucinations and delusions, have faded but quieter, longer-lasting symptoms remain. It was officially listed in the DSM-IV under code 295.60 but was removed from the DSM-5 in 2013 and is no longer used as a formal diagnosis. The concept behind it, however, still describes a real and recognizable stage that many people with schizophrenia experience.
What Residual Schizophrenia Meant as a Diagnosis
Under the previous diagnostic system, a person could be classified with the residual subtype when two conditions were met. First, they no longer had prominent delusions, hallucinations, disorganized speech, or severely disorganized or catatonic behavior. Second, there was still clear evidence of the illness, either through negative symptoms or through milder, “attenuated” versions of active symptoms, such as odd beliefs or unusual perceptual experiences that didn’t rise to the level of full hallucinations or delusions.
The diagnosis required that signs of the disturbance had persisted continuously for at least six months, including at least one month of active-phase symptoms at some point (or less if treatment was successful). In practical terms, this captured people who had been through the worst of a psychotic episode and come out the other side, but whose lives were still noticeably affected by lingering symptoms.
Why It Was Removed From the DSM-5
The American Psychiatric Association eliminated all five schizophrenia subtypes (paranoid, disorganized, catatonic, undifferentiated, and residual) from the DSM-5. The reasoning was straightforward: these subtypes had limited diagnostic stability, low reliability, and poor validity. In other words, a person diagnosed with the residual subtype at one point might not fit that category six months later, and different clinicians often disagreed on which subtype applied. The subtypes also didn’t predict how someone would respond to treatment or how their illness would progress over time.
In place of subtypes, the DSM-5 introduced a dimensional approach. Instead of sorting people into categories, clinicians now rate the severity of core symptom domains on a spectrum. The ICD-11, the international classification system, made the same shift. It dropped schizophrenia subtypes entirely and replaced them with severity ratings across six domains: positive symptoms, negative symptoms, depressive symptoms, manic symptoms, psychomotor symptoms, and cognitive symptoms. So while “residual schizophrenia” no longer appears on a diagnostic report, the symptoms it described are still carefully assessed.
What the Residual Phase Looks Like
The hallmark of the residual phase is the dominance of negative symptoms. These are called “negative” not because they’re bad (though they certainly are burdensome) but because they represent something missing or diminished. The five core negative symptoms are:
- Blunted affect: decreased expression of emotion through facial expressions, eye contact, tone of voice, and gestures
- Alogia: a reduction in the amount someone speaks, sometimes limited to short or empty responses
- Avolition: reduced motivation to initiate or follow through on goal-directed activity, from daily chores to long-term plans
- Asociality: decreased interest in relationships and social interaction
- Anhedonia: a reduced ability to experience pleasure, either during an activity or in anticipation of one
These symptoms tend to be less dramatic than psychotic episodes but often more disabling in daily life. Someone in this phase might struggle to maintain friendships, hold a job, or keep up with personal hygiene, not because they’re experiencing delusions, but because the internal drive to do those things has diminished. To people around them, it can look like laziness or indifference, which makes it particularly isolating.
Some people in the residual phase also have mild leftover positive symptoms. They might hold slightly unusual beliefs or occasionally have fleeting perceptual disturbances that don’t fully qualify as hallucinations. These attenuated symptoms sit in the background rather than dominating the person’s experience.
How Severity Is Rated Now
Under the current ICD-11 system, negative symptoms are rated on a four-point scale that gives a clearer picture of how much they affect someone’s functioning. At the mild end, a person might show subtly flattened emotions, limited spontaneous speech (though they respond normally to questions), and reduced interest in things happening around them while still managing basic daily activities. At the moderate level, emotional expression becomes visibly flat, speech shrinks to short phrases mainly about immediate needs, and hygiene or responsibilities start to slip without significant prompting from others.
At the severe end, a person may describe feeling empty or robotic most of the time, rarely initiate speech even to express basic needs, and be unable to start tasks even with heavy encouragement. This level of severity can lead to serious self-neglect. This graded system replaced the old all-or-nothing subtype label and gives clinicians a way to track changes in these symptoms over time.
Why Negative Symptoms Are Hard to Treat
One of the most frustrating aspects of the residual phase is that the standard antipsychotic medications, which are generally effective at controlling hallucinations and delusions, do not work well for negative symptoms. These medications primarily target the brain’s dopamine pathways, which play a major role in psychotic symptoms but a less direct role in the motivational and emotional deficits that define the residual phase. Primary negative symptoms, meaning those that are part of the illness itself rather than side effects of medication or depression, are particularly resistant to current drug treatments.
This gap means that managing the residual phase often depends more heavily on psychosocial approaches: structured daily routines, supported employment or education programs, social skills training, and therapy aimed at gradually rebuilding engagement with life. These strategies won’t eliminate the underlying symptoms, but they can help a person function at a higher level despite them.
Long-Term Outlook
The trajectory of schizophrenia is more variable than many people assume. A 10-year follow-up study of people after their first episode found that 50% achieved clinical recovery, defined as having only mild symptoms for at least two years while also meeting benchmarks for independent living, employment or education, and social participation. The improvement wasn’t linear. Most gains happened in the first four years, followed by some fluctuation, before stabilizing around the 50% mark by year eight.
At the 10-year point, 46% of participants were employed or in education and 29% were in a relationship. These numbers are more optimistic than older research suggested. They don’t mean the residual phase is easy or temporary for everyone, but they do challenge the idea that schizophrenia is an inevitably declining condition. For many people, the residual symptoms that linger after an acute episode do gradually ease, especially with consistent support and treatment.